186 related articles for article (PubMed ID: 30529060)
1. The Presence of HLA-B75, DR13 Homozygosity, or DR14 Additionally Increases the Risk of Allopurinol-Induced Severe Cutaneous Adverse Reactions in HLA-B*58:01 Carriers.
Shim JS; Yun J; Kim MY; Chung SJ; Oh JH; Kang DY; Jung JW; Cho SH; Kang HR
J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1261-1270. PubMed ID: 30529060
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of the HLA-B
Park HW; Kim DK; Kim SH; Kim S; Chae DW; Yang MS; Oh YK; Lee JP; Jung JW; Shin J; Hwang JH; Kang MG; Kim SM; Kwon SK; Kim HY; Kim MH; Kim SJ; Ryu DR; Cho YJ; Jee YK; Kim SM; Lee EK; Kim JY; Cho HS; Jeong YY; Kim SH; Jun JB; Park JS; Kim GH; Kim S; Jung HY; Lee JM
J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1271-1276. PubMed ID: 30580048
[TBL] [Abstract][Full Text] [Related]
3. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency.
Jung JW; Song WJ; Kim YS; Joo KW; Lee KW; Kim SH; Park HW; Chang YS; Cho SH; Min KU; Kang HR
Nephrol Dial Transplant; 2011 Nov; 26(11):3567-72. PubMed ID: 21393610
[TBL] [Abstract][Full Text] [Related]
4. Impact of the HLA-B(*)58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions.
Ng CY; Yeh YT; Wang CW; Hung SI; Yang CH; Chang YC; Chang WC; Lin YJ; Chang CJ; Su SC; Fan WL; Chen DY; Wu YJ; Tian YC; Hui RC; Chung WH;
J Invest Dermatol; 2016 Jul; 136(7):1373-1381. PubMed ID: 26996548
[TBL] [Abstract][Full Text] [Related]
5. Analysis of HLA-B Allelic Variation and IFN-γ ELISpot Responses in Patients with Severe Cutaneous Adverse Reactions Associated with Drugs.
Klaewsongkram J; Sukasem C; Thantiworasit P; Suthumchai N; Rerknimitr P; Tuchinda P; Chularojanamontri L; Srinoulprasert Y; Rerkpattanapipat T; Chanprapaph K; Disphanurat W; Chakkavittumrong P; Tovanabutra N; Srisuttiyakorn C;
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):219-227.e4. PubMed ID: 29800753
[TBL] [Abstract][Full Text] [Related]
6. HLA-DR9 and DR14 are associated with the allopurinol-induced hypersensitivity in hematologic malignancy.
Jung JW; Kim JY; Yoon SS; Cho SH; Park SY; Kang HR
Tohoku J Exp Med; 2014 Jun; 233(2):95-102. PubMed ID: 24858023
[TBL] [Abstract][Full Text] [Related]
7. An effective strategy to prevent allopurinol-induced hypersensitivity by HLA typing.
Jung JW; Kim DK; Park HW; Oh KH; Joo KW; Kim YS; Ahn C; Lee KW; Cho SH; Min KU; Kang HR
Genet Med; 2015 Oct; 17(10):807-14. PubMed ID: 25634024
[TBL] [Abstract][Full Text] [Related]
8. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study.
Ko TM; Tsai CY; Chen SY; Chen KS; Yu KH; Chu CS; Huang CM; Wang CR; Weng CT; Yu CL; Hsieh SC; Tsai JC; Lai WT; Tsai WC; Yin GD; Ou TT; Cheng KH; Yen JH; Liou TL; Lin TH; Chen DY; Hsiao PJ; Weng MY; Chen YM; Chen CH; Liu MF; Yen HW; Lee JJ; Kuo MC; Wu CC; Hung SY; Luo SF; Yang YH; Chuang HP; Chou YC; Liao HT; Wang CW; Huang CL; Chang CS; Lee MT; Chen P; Wong CS; Chen CH; Wu JY; Chen YT; Shen CY;
BMJ; 2015 Sep; 351():h4848. PubMed ID: 26399967
[TBL] [Abstract][Full Text] [Related]
9. HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population.
Gonçalo M; Coutinho I; Teixeira V; Gameiro AR; Brites MM; Nunes R; Martinho A
Br J Dermatol; 2013 Sep; 169(3):660-5. PubMed ID: 23600531
[TBL] [Abstract][Full Text] [Related]
10. Immunopathogenesis and risk factors for allopurinol severe cutaneous adverse reactions.
Wang CW; Dao RL; Chung WH
Curr Opin Allergy Clin Immunol; 2016 Aug; 16(4):339-45. PubMed ID: 27362322
[TBL] [Abstract][Full Text] [Related]
11. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.
Tassaneeyakul W; Jantararoungtong T; Chen P; Lin PY; Tiamkao S; Khunarkornsiri U; Chucherd P; Konyoung P; Vannaprasaht S; Choonhakarn C; Pisuttimarn P; Sangviroon A; Tassaneeyakul W
Pharmacogenet Genomics; 2009 Sep; 19(9):704-9. PubMed ID: 19696695
[TBL] [Abstract][Full Text] [Related]
12. Unique Clinical Characteristics and Prognosis of Allopurinol-Induced Severe Cutaneous Adverse Reactions.
Park HJ; Yun J; Kang DY; Park JW; Koh YI; Kim S; Kim SH; Nam YH; Jeong YY; Kim CW; Park HK; Kim SH; Kang HR; Jung JW;
J Allergy Clin Immunol Pract; 2019; 7(8):2739-2749.e3. PubMed ID: 31201937
[TBL] [Abstract][Full Text] [Related]
13. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans.
Kang HR; Jee YK; Kim YS; Lee CH; Jung JW; Kim SH; Park HW; Chang YS; Jang IJ; Cho SH; Min KU; Kim SH; Lee KW;
Pharmacogenet Genomics; 2011 May; 21(5):303-7. PubMed ID: 21301380
[TBL] [Abstract][Full Text] [Related]
14. HLA-B*58:01 screening to prevent allopurinol-induced severe cutaneous adverse reactions in Chinese patients with chronic kidney disease.
Wong CS; Yeung CK; Chan CY; Yap DY; Tang SC; Cheung BM; Kwok JS; Chan HH
Arch Dermatol Res; 2022 Sep; 314(7):651-659. PubMed ID: 34213582
[TBL] [Abstract][Full Text] [Related]
15. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.
Hung SI; Chung WH; Liou LB; Chu CC; Lin M; Huang HP; Lin YL; Lan JL; Yang LC; Hong HS; Chen MJ; Lai PC; Wu MS; Chu CY; Wang KH; Chen CH; Fann CS; Wu JY; Chen YT
Proc Natl Acad Sci U S A; 2005 Mar; 102(11):4134-9. PubMed ID: 15743917
[TBL] [Abstract][Full Text] [Related]
16. Real-world evidence of population differences in allopurinol-related severe cutaneous adverse reactions in East Asians: A population-based cohort study.
Sato T; Cheng CL; Park HW; Kao Yang YH; Yang MS; Fujita M; Kumagai Y; Tohkin M; Saito Y; Sai K
Clin Transl Sci; 2021 May; 14(3):1002-1014. PubMed ID: 33382928
[TBL] [Abstract][Full Text] [Related]
17. Comparison between the
Saksit N; Nakkam N; Konyoung P; Khunarkornsiri U; Tassaneeyakul W; Chumworathayi P; Kanjanawart S; Sukasem C; Sangviroon A; Pattanacheewapull O; Tassaneeyakul W
J Immunol Res; 2017; 2017():2738784. PubMed ID: 29392141
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury.
Kaniwa N; Saito Y
J Hum Genet; 2013 Jun; 58(6):317-26. PubMed ID: 23635947
[TBL] [Abstract][Full Text] [Related]
19. Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity?
Dainichi T; Uchi H; Moroi Y; Furue M
Dermatology; 2007; 215(1):86-8. PubMed ID: 17587850
[No Abstract] [Full Text] [Related]
20. Risk factors of allopurinol-induced severe cutaneous adverse reactions in a Thai population.
Saksit N; Tassaneeyakul W; Nakkam N; Konyoung P; Khunarkornsiri U; Chumworathayi P; Sukasem C; Suttisai S; Piriyachananusorn N; Tiwong P; Chaiyakunapruk N; Sawanyawisuth K; Rerkpattanapipat T; Tassaneeyakul W
Pharmacogenet Genomics; 2017 Jul; 27(7):255-263. PubMed ID: 28509689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
